About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/23/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/23/2021.

Quantitative Ultrasound Response of Capsaicin

Clinicaltrials.gov identifier NCT03944889

Recruitment Status Not yet recruiting

First Posted May 10, 2019

Last update posted June 28, 2019

Study Description

Brief summary:

Central Sensitization is an aspect of chronic pain and is associated with over-excitability of the central nervous system. Central Sensitization normally presents itself with other chronic syndromes such as Myofascial Pain Syndrome, so it is difficult to separate the characteristics of the two. The purpose of this study is to determine whether sensitizing healthy muscle using capsaicin, a chilli pepper extract, induces a regional change in ultrasound texture features of the targeted muscle, or the muscles in that are in close proximity. This regional change will be accompanied by electromyography (EMG) recordings to confirm the presence of abnormality. Topical capsaicin and injectable capsaicin will be applied at three different concentrations, 0ug(placebo effect),50ug and 100ug. Research Questions: Does sensitization cause a significant regional change in the texture features of the targeted muscle or surrounding muscles? Is this regional change confirmed by abnormality of motor unit firing rates or EMG amplitudes? Is the response dose dependent? Does the induced central sensitization cause a change in force steadiness? Experimental Protocol: The physician on site will apply surface and intramuscular EMG sensors to the trapezius. A goniometer will be placed on the subjects arm to detect position. Following this, an ultrasound image of the trapezius, supraspinatus and infraspinatus will be taken.The participant will perform an increasing and decreasing contraction.The subject will then have capsaicin injected into their trapezius or applied onto their skin. The exercise and measurements will then be repeated. The ultrasound will be acquired by the Sonosite ultrasound system. The EMG data will be acquired by the Delsys Trigno EMG system for the surface EMG and the Cadwell Sierra Wave system for the intramuscular EMG. The data will be processed through Delsys EMGworks software and MATLAB. Texture features of the pre and post injection ultrasound images will be compared. Decomposition of motor units will allow for the analysis of motor unit action potential firing rate and amplitudes. Analysis of force steadiness will also be calculated via the goniometer. Overall, the findings from this study should present preliminary evidence to inform central sensitization's effects on regional muscle structure changes, functional changes and motor unit activity.

  • Condition or Disease:Central Sensitisation
  • Intervention/Treatment: Drug: Capsaicin
    Device: Delsys Trigno Galileo System
    Device: Cadwell Sierra Wave
    Device: Sonosite Ultrasound Machine
    Device: Goniometer
  • Phase: Early Phase 1
Detailed Description

Myofascial pain syndrome (MPS) is a prevalent chronic pain disorder primarily characterized by myofascial trigger points (MTrP). There is limited knowledge on the pathophysiology and mechanisms underlying MTrP and its development. Ultrasound investigations that have been performed on trigger points can differentiate between active and latent trigger points, but have not characterized the central sensitization aspect of them. The electromyography (EMG) investigations of central sensitization that have been performed mostly use hypertonic saline to induce hyperalgesia, and have demonstrated conflicting results. Central sensitization has been proposed as the primary mechanism underlying MTrP development. Central sensitization is associated with hyperexcitability of neuronal responses to normal or noxious stimuli. There is a need for a study that quantifies regional central sensitization using ultrasound to measure the changing structure, and electromyography to measure specific motor unit activity responses in the muscle. Purpose The purpose of this study is to determine whether sensitizing healthy muscle using capsaicin induces a change in the structural integrity of the affected muscle, and determine if the motor unit frequency and amplitudes change within that region. Central sensitization will be induced using topical capsaicin and injectable capsaicin at three different concentrations. This is an exploratory trial that aims to provide preliminary evidence on whether central sensitization is a direct cause of taut band and MTrP development. Our specific research questions are followings: 1. Does sensitization cause a significant regional change in the texture features of the targeted muscle or surrounding muscles? 2. Does capsaicin induced sensitization elicit a change in motor unit action potential(MUAP) amplitude by approximately 20 to 25% within the region of experimentally induced central sensitization or in the region of texture feature changes? Our hypothesis for this portion of the study is that sensitization modifies the anterior horn cell activity which will be measured by the amplitude of the potentials. 3. Does capsaicin induced sensitization elicit continuous electrical activity as observed in MTrPs? This tests the hypothesis that sensitization creates the presence of continuous low amplitude action potentials. 4. Does capsaicin induced sensitization influence the rate of recruitment of motor units in the muscle within the region induced? Does this occur within the regions identified by the changes in texture features? The recruitment of motor units is normally expected to follow the Henneman size principle.[20-23] Our hypothesis for this portion of the study is that sensitization will cause an aberration in recruitment. If this is demonstrated, then there is modification of the normal processing at both dorsal and ventral horns of the spinal cord. 5. Is there a location dependent EMG response to capsaicin induced sensitization? In other words, do the texture features or EMG responses from muscles that lie anatomically distant from the location of the site of intramuscular capsaicin injection have changes from their baseline calculations? This would test the hypothesis that type III and IV afferents have an influence on the anterior horn cells that lie distant to the ones that are supplying muscle fibers in the vicinity of the stimulated sensory afferents. 6. Is there a dose dependent EMG response at motor units to capsaicin induced sensitization? Here, the hypothesis of causality will be assessed in a preliminary manner. If there is a relationship then further experiments that more thoroughly assess causality will be needed. This proposed study is a single centered, factorial, randomized placebo-controlled trial with two independent variables, depth of capsaicin application(3 levels) and dose of capsaicin(3 levels), for a total of nine treatment arms, three of which are control treatment groups.The first between groups variable will be topical capsaicin application, injectable(intrafascial) and injectable(intramuscular) capsaicin injection. Within each partition, there will be three treatments: control, 50 micrograms, 100 micrograms. The control group will receive a topical skin lotion that is inert and has no sensitization effect. An equal number of participants will be allocated to each of the six treatment groups using an electronic randomization generator. Block randomization will be used to ensure equal allotment into each group. Capsaicin Application and Injection Capsaicin will be applied directly to the region of the innervation zone at the muscle belly to sensitize the neurons within the region of taut band development. Topical and intramuscular capsaicin will be used. The capsaicin formula will be compounded by a registered pharmacist. Topical capsaicin will be delivered in a cream and injectable capsaicin will be intermixed with saline prior to injection. The control group in the topical capsaicin arm will be treated with the cream base used during the experiment without added capsaicin and the injection arm will be injected with saline. A trained medical professional on the research team will apply the topical capsaicin or topical placebo treatments. The region of topical application will measure 5cm squared in the dermatome zone location to cover an area of approximately 25cm2. A trained physician in physical medicine and rehabilitation will deliver injectable capsaicin using a 27-gauge needle at the location of the superior fascia of the upper trapezius muscle with ultrasound guidance. Intramuscular capsaicin will also be injected using ultrasound guidance to avoid the superior or inferior fascia. To confirm the presence of central sensitization, brush allodynia will be used to detect mechanical hyperalgesia outside the region of primary nociception. The size of the region of secondary hyperalgesia will be measured to characterize the extent of central sensitization. This will be accomplished using a tape measure and the perpendicular dimensions of the region of secondary hyperalgesia will be recorded in square centimeters. Experimental Protocol The anatomical location for ultrasound probe and electrode placement will be identified for each participant. The ultrasound probe will be placed on 3 muscles: the trapezius, the supraspinatus, and the infraspinatus. Two ultrasonic pictures will be taken of each. The area will then be cleaned with alcohol and water. The Delsys Galileo sensor, and the intramuscular needle electrode will be placed directly on the trapezius' identified area. Participants will be asked to gently contract their trapezius muscle. They will be instructed to perform a gradually increasing contraction in isometric condition, in a controlled manner. They will hold this contraction at 30% of their maximal voluntary contraction, and then perform a gradually decreasing contraction to rest. This will be performed four times for each type of study intervention and before as well as after each intervention, namely topical control cream, topical capsaicin at 50ug and 100 ug, injection of the superior aspect of the superior fascia followed by intramuscular injection with these two concentrations of capsaicin. The placement of these latter will be verified by ultrasound guidance. The intramuscular needle will then be removed and participants will be bandaged and cared for appropriately by the expert physician performing the experiment. Participants will be re-examined to determine if there were any adverse effects from the experimental procedures. If any occurred, then these will be carefully managed by the medical members of the research team and recorded. Participants will be asked to remain at the lab for an additional 30 minutes to ensure they are well prior to leaving. Ultrasound Analysis Texture analysis will be performed using MATLAB and the image and signal processing toolbox. Analyses will include first order parameters such as mean and standard deviation of the pixel level values, as well as second order parameters, which provide details on the spatial distribution of pixel values. These include co-occurance and run-length matrices, local binary pattern and blob analysis. EMG Analysis The following parameters will be analyzed: the firing times and frequency of individual motor units, motor unit action potential amplitude and shapes, the root mean square value (RMS) of each channel and of the entire signal, the coefficient of variation for force steadiness, and the centroid of the EMG signal in the cranial-caudal and the medial-lateral directions. These procedures will be repeated for each contraction. The results of this study should provide insight into the structural changes and motor changes at the region of sensitization, as well as in adjacent muscles.This will provide further insight as to whether structural changes are accompanied by motor changes within the same region, and inform further investigations into the pathophysiology of myofascial pain. The full study protocol and statistical analysis plan is submitted in the documents section.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 84 participants
  • Allocation: Randomized
  • Intervention Model: Factorial Assignment
  • Intervention Model Description: A single-centered, factorial, randomized, placebo-controlled trial with two independent variables (dosage and depth of application).
  • Masking: Single (Participant)
  • Primary Purpose: Basic Science
  • Official Title: Quantitative Response of Healthy Muscle Following the Induction of Capsaicin
  • Estimated Study Start Date: July 2019
  • Estimated Primary Completion Date: November 2019
  • Estimated Study Completion Date: August 2020
Arms and interventions
Arm Intervention/treatment
Active Comparator: High Dose, Intrafascial
Injection Capsaicin formulation higher dose- injected intrafascially into trapezius
Drug: Capsaicin
Capsaicin 50ug (low dose), Capsaicin 100ug(high dose) will be administered as a topical skin cream and will be intermixed with saline for the injectable solution.

Device: Delsys Trigno Galileo System
This device is a wireless surface EMG device.

Device: Cadwell Sierra Wave
Intramuscular EMG recording machinery

Device: Sonosite Ultrasound Machine
Ultrasound System

Device: Goniometer
A device to measure angular position
Active Comparator: High Dose, Intramuscular
Injection Capsaicin formulation higher dose - injected intramuscularly into trapezius
Drug: Capsaicin
Capsaicin 50ug (low dose), Capsaicin 100ug(high dose) will be administered as a topical skin cream and will be intermixed with saline for the injectable solution.

Device: Delsys Trigno Galileo System
This device is a wireless surface EMG device.

Device: Cadwell Sierra Wave
Intramuscular EMG recording machinery

Device: Sonosite Ultrasound Machine
Ultrasound System

Device: Goniometer
A device to measure angular position
Active Comparator: High Dose, Topical
Capsaicin Cream- higher dosage, applied topically to trapezius
Drug: Capsaicin
Capsaicin 50ug (low dose), Capsaicin 100ug(high dose) will be administered as a topical skin cream and will be intermixed with saline for the injectable solution.

Device: Delsys Trigno Galileo System
This device is a wireless surface EMG device.

Device: Cadwell Sierra Wave
Intramuscular EMG recording machinery

Device: Sonosite Ultrasound Machine
Ultrasound System

Device: Goniometer
A device to measure angular position
Active Comparator: Low Dose, Intrafacial
Injection Capsaicin formulation low dose- injected intrafascially into trapezius
Drug: Capsaicin
Capsaicin 50ug (low dose), Capsaicin 100ug(high dose) will be administered as a topical skin cream and will be intermixed with saline for the injectable solution.

Device: Delsys Trigno Galileo System
This device is a wireless surface EMG device.

Device: Cadwell Sierra Wave
Intramuscular EMG recording machinery

Device: Sonosite Ultrasound Machine
Ultrasound System

Device: Goniometer
A device to measure angular position
Active Comparator: Low Dose, Intramuscular
Injection Capsaicin formulation low dose - injected intramuscularly into trapezius
Drug: Capsaicin
Capsaicin 50ug (low dose), Capsaicin 100ug(high dose) will be administered as a topical skin cream and will be intermixed with saline for the injectable solution.

Device: Delsys Trigno Galileo System
This device is a wireless surface EMG device.

Device: Cadwell Sierra Wave
Intramuscular EMG recording machinery

Device: Sonosite Ultrasound Machine
Ultrasound System

Device: Goniometer
A device to measure angular position
Active Comparator: Low Dose, Topical
Capsaicin Cream- low dosage, applied topically to trapezius
Drug: Capsaicin
Capsaicin 50ug (low dose), Capsaicin 100ug(high dose) will be administered as a topical skin cream and will be intermixed with saline for the injectable solution.

Device: Delsys Trigno Galileo System
This device is a wireless surface EMG device.

Device: Cadwell Sierra Wave
Intramuscular EMG recording machinery

Device: Sonosite Ultrasound Machine
Ultrasound System

Device: Goniometer
A device to measure angular position
Placebo Comparator: Placebo Topical
Placebo Cream, applied topically to trapezius muscle
Device: Delsys Trigno Galileo System
This device is a wireless surface EMG device.

Device: Cadwell Sierra Wave
Intramuscular EMG recording machinery

Device: Sonosite Ultrasound Machine
Ultrasound System

Device: Goniometer
A device to measure angular position
Placebo Comparator: Placebo, Intrafascial
Injection placebo(saline)- injected intrafascially into trapezius
Device: Delsys Trigno Galileo System
This device is a wireless surface EMG device.

Device: Cadwell Sierra Wave
Intramuscular EMG recording machinery

Device: Sonosite Ultrasound Machine
Ultrasound System

Device: Goniometer
A device to measure angular position
Placebo Comparator: Placebo, Intramuscular
Injection placebo (saline) - injected intramuscularly into trapezius
Device: Delsys Trigno Galileo System
This device is a wireless surface EMG device.

Device: Cadwell Sierra Wave
Intramuscular EMG recording machinery

Device: Sonosite Ultrasound Machine
Ultrasound System

Device: Goniometer
A device to measure angular position
Outcome Measures
  • Primary Outcome Measures: 1. Motor Unit Action Potential Firing Rate [ Time Frame: up to 6 months ]
    Firing rate will be determined using EMGworks software and compared with baseline firing rates.
  • 2. Root Mean Square EMG values [ Time Frame: up to 6 months ]
    Root mean square values will be compared with baseline values using EMGworks software.
  • 3. Coefficient of Variation- Force steadiness [ Time Frame: up to 6 months ]
    Force steadiness will be measured by the coefficient of variation (standard deviation/mean) using EMGworks software, validated through the goniometer measurements
  • 4. Motor Unit Action Potential Amplitudes [ Time Frame: up to 6 months ]
    Amplitudes will be measured from the overall amplitude difference from baseline for each motor unit using EMGworks software
  • 5. Centroid of Frequency Spectrum [ Time Frame: up to 6 months ]
    Centroid frequency will be measured and the frequency shift of the signal will be compared with baseline. Measured using EMGworks software
  • 6. Texture Feature Analysis [ Time Frame: up to 6 months ]
    91 features will be extracted using MATLAB, then a reduction of variables will be performed using principal component analysis. The experimental data will be compared with baseline results.
  • Secondary Outcome Measures: 1. Severity of pain [ Time Frame: up to 6 months ]
    Pain, or burning sensation measured by the visual analogue scale(0-no pain to 10-worst pain imaginable)
Eligibility Criteria
  • Ages Eligible for Study: 18 to 64 Years (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: Yes
Criteria

Inclusion Criteria:

- healthy with no past medical history

- a visual analogue score below 3 indicating low pain severity, ideally who complain of
no pain

- right or left handed

- normal body mass index

- have sufficient knowledge of the English language to provide informed consent and
understand the protocols

- agree to sign a consent form.

Exclusion Criteria:

- history of pain

- detectable myofascial trigger points upon physical examination

- history of pain related disturbances such as poor sleep

- cognitive disturbances, psychiatric disorders

- history of general medical disorder that may affect the outcome of the study such as
diabetes mellitus

- history of cervical radiculopathies

- history of inflammatory arthropathy

Contacts and Locations
Contacts

Contact: VALERIE F EVANS, B.Eng 6478597502 valerie.evans@mail.utoronto.ca

Contact: Dinesh M Kumbhare, MD,PhD 416-597-3422 ext 4612 dinesh.kumbhare@uhn.ca

Locations
Sponsors and Collaborators

Toronto Rehabilitation Institute

Investigators

Principal Investigator: Dinesh M Kumbahre, MD,PhD Toronto Rehabilitation Institute

More Information